225
Views
3
CrossRef citations to date
0
Altmetric
Original research

Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model

, ORCID Icon, , ORCID Icon & ORCID Icon
Pages 1011-1016 | Received 16 Jul 2020, Accepted 20 Oct 2020, Published online: 02 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Qian Ding, Dane Shiltz, Dana Hossami & Alison M Konieczny. (2022) The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States. Expert Review of Pharmacoeconomics & Outcomes Research 22:8, pages 1231-1241.
Read now
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Juliana Alvares-Teodoro & Francisco De Assis Acurcio. (2022) Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert Review of Pharmacoeconomics & Outcomes Research 22:3, pages 473-479.
Read now

Articles from other publishers (1)

Ahmad Gholami, Jassem Azizpoor, Elham Aflaki, Mehdi Rezaee & Khosro Keshavarz. (2021) Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International 2021, pages 1-12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.